Skip to main content
. 2024 Sep 16;40(2):491–503. doi: 10.1007/s00467-024-06487-2

Table 4.

Risk factors for the development of antibody-mediated rejection

Risk factors for ABMR# development Unadjusted HR (95% CI) p value Adjusted HR (95% CI) p value
Age at KTx, years 1.06 (1.01–1.13) 0.027 1.06 (1.00–1.13) 0.048
 > 1 KTx (> 1 versus 1) 2.39 (1.14–5.02) 0.022 1.85 (0.85–4.04) 0.122
HLA-DR mismatch (0 versus 1 or 2) 1.80 (1.13–2.90) 0.014 1.85 (1.13–3.02) 0.015
CMV IgG negative recipient and negative donor 0.39 (0.17–0.88) 0.024 0.40 (0.18–0.90) 0.027
Preformed HLA-DSA 2.37 (1.02–5.53) 0.045 1.30 (0.54–3.14) 0.563
TCMR/borderline rejection 1.14 (0.53–2.43) 0.743
BKPyV nephropathy 0.99 (0.13–7.31) 0.99
de novo class I HLA-DSA only1,2 3.07 (0.73–13.0) 0.127
de novo class II HLA-DSA only1,2 3.38 (1.49–7.63) 0.003 3.78 (1.62–8.82) 0.002
de novo class I and II HLA-DSA1,2 4.42 (1.68–11.6) 0.003 5.00 (1.75–14.2) 0.001

ABMR antibody-mediated rejection, CI confidence interval, DSA donor-specific antibodies, HLA human leukocyte antigen, HR hazard ratio, KTx kidney transplantation, TCMR T-cell mediated rejection

1De novo HLA-DSA and histopathologic diagnoses were regarded as time-dependent co-variables

2Data were reported by the respective transplant centers according to the center-specific cut-off for HLA-DSA positivity

#ABMR includes acute ABMR, chronic active ABMR, and mixed rejections